Alerta

LEVERAGING CIRCULATING ORAL MICROBIOME VESICLE-ASSOCIATED PROTEINS FOR THE DIAGNOSIS AND PROGNOSIS OF MIXED DEMENTIAS

Resumen de: EP4745575A1

0001 The present invention refers to the use of an oral microbiome-derived extracellular vesicle associated protein (OMEVP) in the diagnosis or prognosis of mixed dementias in a biological sample obtained from a subject, wherein the OMEVP is the Chaperone protein DnaK or a fragment thereof. Furthermore, the present inventions refers to the method of diagnosis or prognosis of mixed dementia in a subject comprising assessing the level of an OMEVP in a biological sample obtained from a subject.

NON-PURIFIED CSF AND CSF-DERIVED EVS MARKERS FOR PATIENTS WITH ALZHEIMER'S, PARKINSON'S AND LEWY BODY DEMENTIA

Resumen de: EP4492033A1

The present invention is directed to the field of dementia, providing non-purified CSF and CSF-derived EVs markers for differential dementia diagnosis in patients with Alzheimer's, Parkinson's and Lewy body dementia. It not only provides the markers, but equally the method in using said markers for differential dementia diagnosis amongst the aforementioned patients.

ANTIMICROBIAL PEPTIDES

Resumen de: WO2025019457A1

Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD, based on presence of antimicrobial peptides (AMPs) at levels that differ from those in control individuals.

使用神经丝轻链免疫测定的方法

Resumen de: WO2025090763A1

Methods, kits and compositions of detecting analytes, typically analytes relevant to neurodegenerative diseases such as neurofilament light chain, in a sample are described herein using chemiluminescent labels. Solid supports, reagents, and compounds for use in these methods are also described. Typically, the methods involve specific assay formats which provide the requisite high resolution for detecting low concentrations of analytes in samples and may be used in positions of the healthcare ecosystem close to the patient. These methods, systems, and apparatuses may afford early detection and prognosis of a wide variety of neurodegenerative diseases such as Alzheimer's disease and multiple sclerosis.

抗ＮＭＩモノクローナル抗体又はその抗原結合断片及びその使用

Resumen de: WO2024213001A1

Provided are an anti-NMI monoclonal antibody or an antigen-binding fragment thereof, and the use thereof. The antibody or the antigen-binding fragment thereof has good binding activity to the NMI protein, has high affinity to the NMI protein, can be used for detecting the presence or level of NMI protein in a sample and performing diagnosis, auxiliary diagnosis or prognostic evaluation of diseases or conditions related to the abnormal high level and/or the activity of NMI, and is used for removing the NMI protein in the body fluid and preventing and treating diseases or conditions related to the abnormal high level and/or the activity of NMI.

シンタキシン結合タンパク質１欠損に関連する障害の治療のための組成物及び方法

Resumen de: JP2026515814A

0001 本開示は、アデノ随伴ウイルス（ＡＡＶ）カプシドバリアントを使用する送達を介してＳＴＸＢＰ１タンパク質の発現を変化させる、例えば、増強するための組成物及び方法に関する。本開示の組成物及び方法は、ＳＴＸＢＰ１脳症、又は別のＳＴＸＢＰ１関連障害を有すると診断されたか、又はそれを有すると疑われる対象の治療において有用である。

Ensayo de detección de alfa-sinucleína

Resumen de: US2019302128A1

0001 A method of detecting the presence of alpha-synuclein aggregation in a biological sample is provided whereby a biological sample is mixed with a reaction sample comprising a population of beads, a fluorophore adapted to bind to protein aggregates and to increase fluorescence when bound to protein aggregates, and alpha-synuclein or a fragment or variant thereof to form a reaction mixture, the reaction mixture is illuminated and at the same time incubated with intermittent agitation cycles, wherein a significant increase in the fluorescence of the reaction mixture during incubation is indicative of the presence of aggregates of alpha-synuclein in the biological sample. Method of diagnosing alpha-synucleinopathies such as Parkinson's disease or Dementia with Lewy Bodies.

スプライシングを監視する方法

Resumen de: WO2024229504A1

The present invention relates to methods for identifying the splicing of RAGE pre-mRNA resulting in the inclusion of exon 9b and/or exclusion of exon 10 in a subject in a subject who has received, or is receiving an antisense oligonucleotide that modulates RAGE pre-mRNA splicing. In one aspect, the present invention provides a method for determining endogenous soluble receptor for advanced glycation end products (RAGE) level in the lung of a subject, the method comprising: determining the presence of endogenous soluble RAGE in a blood sample from a subject who has received or is receiving a treatment administered to their respiratory tract, wherein the treatment increases endogenous soluble RAGE, wherein the level of endogenous soluble RAGE in the blood sample correlates with the endogenous soluble RAGE level in the lung of the subject.

一种检测全血样本中胶质纤维酸性蛋白的化学发光免疫分析测定试剂盒及制备方法

Resumen de: CN122063265A

本发明公开了一种检测全血样本中胶质纤维酸性蛋白的化学发光免疫分析测定试剂盒及制备方法，该测定试剂盒包括：R1试剂：链霉亲和素包被的磁性微粒，R3试剂：吖啶酯标记的GFAP单克隆抗体，R4试剂：生物素标记的GFAP单克隆抗体，其中，所述R3试剂和R4试剂溶于稀释液中，所述稀释液为包含适配全血样本体系的消泡剂的柠檬酸缓冲液，所述消泡剂为聚二甲基硅氧烷。全血样本经采集后可直接上机检测，无需进行血清、血浆的分离处理，能有效解决传统血清、血浆样本检测中样本处理耗时久、检测周转周期长的痛点；同时，添加消泡剂阻止“气泡‑蛋白复合物”的形成，显著改善试剂的检测精密度。

一种兔源BD-tau单克隆抗体及其制备方法和应用

Resumen de: CN122060062A

0001 本公开提供了一种抗人大脑来源BD‑tau蛋白的兔源单克隆抗体及其制备方法和应用，属于生物检测、生物工程技术领域。抗人大脑来源BD‑tau蛋白的兔源单克隆抗体包括轻链可变区和重链可变区，单克隆抗体包括HZK35‑B0028和HZK35‑B0038。本公开开发了识别BD‑tau的两种兔源单克隆抗体，其不会与非BD‑tau蛋白或其他位点的BD‑tau蛋白发生交叉反应，能够高度特异性地结合BD‑tau，并以此开发出更具特异性的相关体液标记物检测试剂盒。

Complex for detecting collagenase containing metal nanoparticles and gelatin diagnostic kit for degenerative disease containing the same and method for manufacturing the complex for detecting collagenase

Resumen de: KR20260071607A

0001a 본 발명은 금속 나노입자 및 젤라틴을 포함하는 콜라게나아제 검출용 조성물, 이를 포함하는 퇴행성 질환의 진단 키트 및 상기 콜라게나아제 검출용 조성물의 제조방법에 관한 것으로, 젤라틴의 분해 및 금속 나노입자 간의 응집 작용에 의한 색상 변화를 통해 콜라게나아제의 존재 여부를 용이하게 검출할 수 있다. 더 나아가, 상기 콜라게나아제 검출용 조성물의 제조 방법 및 상기 조성물을 이용한 콜라게나아제 검출 방법을 제공할 수 있으며, 상기 콜라게나아제 검출용 조성물을 포함하여, 퇴행성 질환의 바이오마커인 콜라게나아제를 비색 검출할 수 있는 퇴행성 질환의 진단 키트 또한 제공할 수 있다.

一种基于G-四链体设计的荧光传感器及其在检测Aβ42中的应用

Resumen de: CN122060743A

本发明公开了一种基于G‑四链体设计的荧光传感器及其在检测Aβ42中的应用，属于生物检测技术领域。本发明通过寡核苷酸分子裁剪技术获得了一种高亲和力G‑四链体结构适配体，该适配体可特异性地结合AD生物标志物Aβ42。结合硫黄素T荧光介导剂，我们还开发了一种基于G‑四链体辅助结构转变的高通量荧光适配体传感器。该传感器不仅实现了从0.01 pg到100 pg Aβ42的宽检测窗口，检测限达3 fg/ml，还具备良好的并行检测能力，可同时分析多个样品，显著提升了检测效率。该传感器在临床血清样本中成功应用于Aβ42检测，展现出优异的重复性和稳定性。

一种靶向铁调节蛋白IRPs的核酸适配体及其应用

Resumen de: CN122060746A

0001 本发明属于生物医药技术领域，具体涉及一种靶向铁调节蛋白IRPs的核酸适配体及其应用。所述核酸适配体包含：如SEQ ID NO.1所示的核苷酸序列，或与SEQ ID NO.1所示的核苷酸序列具有至少90%序列同一性、且保留特异性结合铁调节蛋白IRPs的RNA结合构象功能的变体序列；至少一个位于所述核酸适配体的核苷酸序列内部的经修饰的核苷酸或核苷酸间键；位于所述核酸适配体的核苷酸序列末端的标记或功能基团修饰。本发明提供的该核酸适配体经修饰后具备优异的核酸酶抗性、细胞透膜性和成像性能，适用于IRPs活性检测、铁代谢相关疾病的诊断、治疗和机制研究。

细胞培养和阻抗监测装置及其应用

Resumen de: CN122060592A

0001 本发明提出了一种细胞培养和阻抗监测装置及其应用，具体地，本发明提出了一种装置，包括：多孔膜层、上层细胞培养室和下层细胞培养室；所述多孔膜层设置于上层细胞培养室和下层细胞培养室之间；所述多孔膜层包括微孔绝缘层、导电层；所述导电层包括多电极阵列，所述多电极阵列包括预定数目的电极，各所述电极设置于所述微孔绝缘层内部包覆，在各所述电极一端顶点设置开窗区，所述开窗区设置于多孔膜层的至少一侧表面。本发明提出的装置在不影响细胞正常生长和物质交换的前提下，能够实现对细胞屏障阻抗和电生理活动的长期、实时、高空间分辨率监测。

化合物、女性ホルモン検査薬及び女性ホルモンを検査する方法

Resumen de: JP2026080987A

【課題】簡易的かつ特異的に女性ホルモンを検出できる化合物、女性ホルモン検査薬及び女性ホルモンを検査する方法を提供すること。【解決手段】下記式（１）で表される化合物。JPEG2026080987000033.jpg5105［式（１）中、Ｆ１、Ｆ２、Ｌ１、Ｌ２及びＸ０は、明細書中で規定する通り。］【選択図】なし

血液検査データと機械学習モデルを用いた神経変性疾患の発症と進行の予測

Nº publicación: JP2026515409A 18/05/2026

Solicitante:

モルリサーチアプリケーションズリミテッド

Resumen de: JP2026515409A

0001 血液検査データと機械学習モデルを用いて神経変性疾患の発症と進行を予測する方法およびシステムが開示される。本方法は、先行期間にわたる対象被検者の血液検査値を受信し、血液検査データから特徴を抽出し、訓練された予測モデルを適用して、抽出された特徴に基づいて神経変性疾患の発症のリスクスコアを計算することを含む。本システムは、コードを実行して方法を実行するプロセッサを有し、スタンドアロンアプリケーションやクラウドベースのサービスとして実装することも、医療システムと統合することもできる。予測モデルは、ラベル付きデータを用いた教師あり学習で訓練され、統計モデルや機械学習アルゴリズムを含むことができる。本システムおよび本方法は、神経変性疾患の早期発見、個別化されたリスク予測、既存の医療インフラとの統合を可能にする。血液検査データと機械学習技術を活用することで、患者の転帰が改善される可能性がある。 【選択図】図２